MedPath

New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Not Applicable
Recruiting
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Other: Muscular MRI
Other: Electrophysiological exam
Other: Spinal cord MRI
Other: Brain MRI
Registration Number
NCT04691011
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Brief Summary

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Patients will be adults with a diagnosis of ALS.
  • Healthy controls will also be recruited and will be age- and gender-matched to patients.
  • Patients able to undergo a brain MRI for approximately an hour.
Exclusion Criteria
  • Subjects with other psychiatric or CNS or PNS diseases.
  • Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an MRI scan.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Spinal cordElectrophysiological exam-
MuscleElectrophysiological exam-
MuscleMuscular MRI-
Spinal cordMuscular MRI-
BrainMuscular MRI-
BrainElectrophysiological exam-
Spinal cordSpinal cord MRI-
BrainBrain MRI-
Primary Outcome Measures
NameTimeMethod
Disease progression using MRIChange from Baseline and at Month 6

Muscular, brain and spinal cord MRI (brain sodium concentration, muscular volume of members, measure of transversal area for spinal cord)

Secondary Outcome Measures
NameTimeMethod
Alterations of metabolic and funtional brainBaseline and Month 6

Multiparametric MRI (diffusion parameters, myelin parameters, quantification of fat-infiltration and oedema)

Link between MRI and clinical scalesBaseline and Month 6

ALSFRS score, MRC score, ECAS score

Link between MRI and MUNIXBaseline and Month 6

For muscle, brain and spinal cord group

Trial Locations

Locations (1)

Shahram Attarian

🇫🇷

Marseille, France

© Copyright 2025. All Rights Reserved by MedPath